Using fosfomycin in the treatment of acute uncomplicated cystitis. An ob-gyn perspective


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Urinary tract infections (UTIs) are among the most common bacterial infections worldwide. A significant number (up to 60%) of consultations with a specialist is associated with acute or recurrent cystitis. 20-25% of women suffer from acute cystitis over the life course, one in three of them has a disease relapse within a year. The disease leads to the patients’ reduced quality of life, adversely affecting social and labour activity. The goal of treating an uncomplicated UTIs is to eliminate the symptoms, eradicate the pathogen, prevent relapse, prevent complications and improve the quality of life of the patient. According to the Russian clinical recommendations for urology, fosfomycin trometamol, furazidin potassium salt with magnesium carbonate and nitrofurantoin are the drugs of choice. Given the high efficacy and safety of the fosfomycin oral form, as well as the single-dose antibacterial drug regimen, this medical agent has several undeniable advantages: it is most convenient for the patient (which contributes to its compliance), reduces the cost of treatment, and decreases the possibility of side effects compared with longer antibiotics regimen.

Full Text

Restricted Access

About the authors

Olga I. Lisitsina

National Medical Research Center of Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov, Ministry of Healthcare of Russia

Email: o_yazykova@inbox.ru
intern of General Surgery

References

  1. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 2011; 52(5): e103-20.
  2. Mannucci C., Dante G., Miroddi M., Facchinetti F., D’Anna R., Santamaria A. et al. Vigilance on use of drugs, herbal products, and food supplements during pregnancy: focus on fosfomycin. J. Matern. Neonatal Med. 2019;32(1): 125-8.
  3. Leeper C., Lutzkanin A. Infections during pregnancy. Prim. Care. 2018; 45(3): 567-86.
  4. Зайцев А.В., Касян Г.Р., Спивак Л.Г. Цистит. В. кн.: Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю., ред. Урология. Российские клинические рекомендации. М.: Медфорум; 2017: 501-18.
  5. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. North Am. 2014; 28(1): 1-13.
  6. Балушкина А.А., Кан Н.Е., Тютюнник В.Л. Современный взгляд на терапию инфекций мочевыводящих путей у беременных. РМЖ. Медицинское обозрение. 2018; 2(8-1): 37-40.
  7. Сухих Г.Т., ред. Беременность и роды при заболеваниях мочевыводящих органов. М.; 2009.
  8. Рафальский В.В. Антибиотикорезистентность возбудителей неосложненных инфекций мочевых путей в Российской Федерации. Вестник урологии. 2018; 6(3): 50-6.
  9. Chlabicz S., Leszczynska K., Lukas W., Gualco L., Schito G., Naber K.G. Uncomplicated lower urinary tract infections in females--clinical aspects, aetiology and antimicrobial resistance epidemiology. Results of the ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study in Poland and their implications for empiric therapy. Przegl. Epidemiol. 2011; 65(2): 345-51.
  10. Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Шевелев А.Н., Гринев А.В., Перепанова Т.С., Козлов Р.С., Коган М.И. Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования «ДАРМИС» (2010-2011). Клиническая микробиология и антимикробная химиотерапия. 2012; 14(4): 280-302.
  11. Каптильный В.А. Острый цистит в практике акушера-гинеколога. Медицинский совет. 2018; 13: 114-23.
  12. Bader M.S., Loeb M., Brooks A.A. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad. Med. 2017; 129(2): 242-58.
  13. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., Athanasiou S. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 2010; 65(9): 1862-77.
  14. Колонтарев К.Б., Зайцев А.В., Пушкарь Д.Ю. Сравнительный анализ антибактериальной терапии острого цистита. Урология. 2013; 3: 112-22.
  15. Chen Y.T., Ahmad Murad K., Ng L.S., Seah J.T., Park J.J., Tan T.Y. In vitro efficacy of six alternative antibiotics against multidrug resistant escherichia coli and Klebsiella pneumoniae from urinary tract infections. Ann. Acad. Med. Singapore. 2016; 45(6): 245-50.
  16. Aris P., Boroumand M.A., Rahbar M., Douraghi M. The activity of fosfomycin against extended-spectrum beta-lactamase-producing isolates of enterobacteria-ceae recovered from urinary tract infections: a single-center study over a period of 12 years. Microb. Drug Resist. 2017; 24(5): 607-12.
  17. Yu H.S., Hwang E.C., Jung S.I., Kang T.W., Kwon D.D., Chung H.S. et al. Antimicrobial susceptibilities of urinary extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin in health care associated urinary tract infection. Eur. Urol. 2015; 14(2, Suppl.): e249.
  18. Mezzatesta M.L., La Rosa G., Maugeri G., Zingali T., Caio C., Novelli A., Stefani S. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens. Int. J. Antimicrob. Agents. 2017;49(6): 763-6.
  19. Fosfomycin for UTIs. Drug Ther. Bull. 2016; 54(10): 114-7.
  20. Яровой С.К. Место фосфомицина в медикаментозной терапии заболеваний мочеполовой системы. Экспериментальная и клиническая урология. 2013; 4: 115-20.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies